Selexis SA Establishes US Subsidiary and Appoints Andrew F. Sandford Vice-President of Business Development and Licensing
Published: Apr 11, 2007
GENEVA and MARLBOROUGH, Mass., April 10 /PRNewswire/ -- Selexis SA, a Swiss-based biotechnology company which specializes in technologies which enable significantly improved drug discovery, development, and cGMP production, and offers expert services for the rapid development of high-yield and stable cell lines, is announcing the establishment of its US-based subsidiary, Selexis, Inc. (Marlborough, MA). Selexis Inc. is also announcing the appointment of Andrew F. Sandford serving as Vice-President of Business Development and Licensing.
"Establishing Selexis, Inc. allows us to more effectively support the wider application of Selexis technologies while strengthening our relationships with our existing customer base," said Dr. Igor Fish, President and CEO. "Additionally, we are thrilled to have a high caliber and experienced individual such as Andrew join the Selexis team. Andrew's background in the commercialization of enabling technologies in the biotechnology sector will help Selexis realize even greater growth."
Andrew F. Sandford brings over 15 years experience as a business development executive in the healthcare and biotechnology sectors. Prior to joining Selexis, Sandford was with The Dow Chemical Company, Ventures Business Unit - Dowpharma. There, he led a diverse team in the development and launch of Pfenex Expression Technology(TM) a novel recombinant protein production platform. Most recently, Sandford was part of the business development group at Cambrex Biopharma, which is now part of Lonza Biologics.About Selexis:
Selexis is a privately held biotechnology company dedicated to the development of innovative technologies and expert services for the development of stable, high yield mammalian cell lines used in recombinant protein manufacturing as well as enabling technologies to significantly improve discovery research, production process development, and biologic drug product manufacturing. The company's core intellectual property portfolio is based on the discovery and application of enabling genetic elements that control the dynamic organization of chromatin within all mammalian cells. These genetic elements enable the stable expression of certain biologics while significantly reducing the discovery and manufacturing costs of most others. The Selexis core technologies also enable applications in the emerging biotechnology area of gene and stem cell therapy.
NOTE: MARtech(TM) and SURE Cell Line Development SM are trademarks of Selexis SA.
Pfenex Expression Technology is a trademark of Dow Chemical Company.Selexis SA
CONTACT: EUROPE, Igor Fisch, Ph.D., +41 (0)22 308 93 60, orIgor.firstname.lastname@example.org, or UNITED STATES, Andrew F. Sandford,+1-617-595-5769, or email@example.com